GlassScriptPhysician profile
David H Bulbin
NPI 1659679959
$379,015.32
in general payments reported to CMS, 2019-2025
19 companies · $101K in 2025
The $101K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $9,156 · 2021: $4,856 · 2022: $38K · 2023: $82K · 2024: $123K · 2025: $101K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $207K · Travel and Lodging: $65K · Consulting Fee: $20K · Food and Beverage: $9,856 · Long Term Medical Supply Or Device Loan: $3,500 · Education: $77.99 · Gift: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $207,469.75 |
| Travel and Lodging | $64,706.12 |
| Consulting Fee | $20,198.00 |
| Food and Beverage | $9,856.28 |
| Long Term Medical Supply Or Device Loan | $3,500.00 |
| Education | $77.99 |
| Gift | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $123,550.92 | 2022-2025 | Tavneos, Uplizna, Otezla |
| Alexion Pharmaceuticals, INC. | $98,607.81 | 2019-2025 | Strensiq |
| Abbvie INC. | $78,124.77 | 2021-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $31,418.21 | 2019-2025 | Cosentyx |
| Genzyme Corporation | $21,082.70 | 2020-2025 | |
| Glaxosmithkline, LLC. | $20,511.62 | 2024-2025 | Benlysta |
| Exo Imaging, INC. | $3,550.00 | 2024 | Exo Iris |
| Horizon Therapeutics Plc | $1,279.07 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $139.59 | 2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $135.13 | 2022-2025 | Saphnelo |
| Ucb, INC. | $132.59 | 2025 | Bimzelx |
| Sobi, INC | $120.32 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $113.22 | 2019 | |
| Lilly USA, LLC | $73.71 | 2023 | Taltz |
| Organon LLC | $56.16 | 2025 | Hadlima, Renflexis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $43.22 | 2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.59 | 2025 | |
| Genentech USA, INC. | $25.68 | 2025 | Gazyva |
| Pfizer INC. | $15.01 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bulbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.